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Abstract 
 
Cardiovascular disease continues to be the number one cause of death in the 
United States, with heart failure patients expected to increase to >8 million by 
2030. Mechanical circulatory support (MCS) devices are now better able to 
manage acute and chronic heart failure refractory to medical therapy, both as 
bridge to transplant or as bridge to destination. Despite significant advances in 
MCS device design and surgical implantation technique, it remains difficult to 
predict response to device therapy. Heart rate variability (HRV), measuring the 
variation in time interval between adjacent heartbeats, is an objective device 
diagnostic regularly recorded by various MCS devices that has been shown to 
have significant prognostic value for both sudden cardiac death as well as all-
cause mortality in congestive heart failure (CHF) patients. Limited studies have 
examined HRV indices as promising risk factors and predictors of complication 
and recovery from left ventricular assist device therapy in end-stage CHF patients. 
If paired with new advances in machine learning utilization in medicine, HRV 
represents a potential dynamic biomarker for monitoring and predicting patient 
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status as more patients enter the mechanotrope era of MCS devices for 
destination therapy. 
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Introduction 
 
Advanced heart failure (HF) is a growing epidemic with high morbidity and 
mortality, with patients in HF in the United States expected to increase to >8 
million by 2030 [1]. The gold standard for the treatment of end stage HF remains 
orthotopic heart transplantation. With the ongoing shortage of available organs for 
heart transplantation and new UNOS criteria for allocation, utilization of 
mechanical circulatory support (MCS) device, especially the left ventricular assist 
device (LVAD), has increased greatly for managing acute and chronic HF, the 
latter of which is refractory to medical treatment. MCS devices are now 
utilized both as a bridge to transplant or as a bridge to alternate destination 
therapy. The application of continuous-flow LVADs demonstrates 1-year survival 
of up to 80% as compared to that of heart transplantation at 86% (1). Although the 
durability of MCS devices allows long-term beneficial effects of mechanical 
unloading, this strategy is not free of complications and device-related issues, 
which makes this therapy a challenge to apply to a broader population. The main 
complications can be grouped into five categories, including bleeding 
(gastrointestinal bleeding 18-40%), pump thrombosis (8.4% at 3 months after 
LVAD implantation), driveline infection (17-30%), stroke (up to 17%), and right-
sided HF (10-30%) (1). Despite significant advances in MCS device design and 
surgical implantation technique, it remains difficult to predict recovery response to 
device therapy. 
There is a need for a consistent, reproducible, and cost-effective method of 
determining cardiac recovery in patients who receive emerging novel therapeutics 
for advanced and end-stage HF. It has been proposed that a major contributor to 
deteriorating severe end-stage HF is a prominent inappropriately elevated 
sympathetic activation outflow to the heart, in conjunction with a concurrent vagal 
outflow withdrawal (2). Various mechanisms of disease propagation secondary to 
this autonomic dysregulation have been proposed, including abnormal 
transduction of beta-adrenergic signals, induced tachyarrhythmias, renin-
angiotensin-aldosterone-system (RAAS) activation, myocardial remodeling, and 
accelerated myocardial cell death (2). With the increasing use of ventricular assist 
devices (VADs) in end-stage HF, objective device diagnostics are available for 
analysis. 
Heart rate variability (HRV), an accessible diagnostic measure, defines the 
variation in time interval between adjacent heartbeats. It is most commonly 
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measured utilizing R-R intervals from patients' electrocardiograms, i.e. via 24-hour 
Holter monitoring. Previous literature has shown that a reduction in various HRV 
indices has been both associated with and an independent predictor of higher risk 
for all-cause mortality in healthy patients, CHF patients, and post-AMI patients 
(2,3). HRV can be defined in different ways, including time-domain indices, 
frequency-domain indices, and non-linear indices (3).  
Time-domain analyses utilize the normal R-R intervals of ventricular contractions, 
with various measurements calculated from these intervals to quantify the 
variability of each interbeat interval (IBI). The monitoring periods over which time-
domain indices may be measured can range from as short as <1 min to as long as 
>24 hrs. SDNN is the standard deviation of all normal R-R intervals in a 24-hour 
time period. SDANN is the standard deviation of 5-minute averages of normal R-R 
intervals. ASDNN is the average of SDNN’s over 5 minutes. rMSSD is the root-
mean square of the difference between successive R-R intervals. pNN50 is the 
number of instances in 1 hour in which 2 consecutive R-R intervals differs by more 
than 50ms over 24 hours.  
Frequency-domain indices involve computing the beat-to-beat timing (R-R 
intervals) with a Fast Fourier Transformation, to determine the amount of 
component HRV signal that exists within four varied frequency bands (ULF, VLF, 
LF, HF) similar to the component wavelengths of light. The ULF-band is defined as 
0.003 Hz, with no current understanding of the mechanism from which it is 
generated physiologically. The VLF-band is defined as 0.003-0.04 Hz and is 
proposed to be related to thermoregulation of vasomotor tone. The LF-band is 
defined as 0.04-0.15Hz and is proposed to represent the body's natural baroreflex 
mechanism, reflecting both SNS and PNS tone. The HF-band is defined as 0.15-
0.40Hz and is proposed to be influenced by the parasympathetic nervous system 
outflow to the heart as well as respiratory frequency. The LF/HF ratio is intended to 
estimate the ratio of SNS to PNS activity (sympathovagal balance). Total power is 
defined as the estimated sum of the frequencies. There are also several non-linear 
HRV indices. Triangular index (TI) is calculated by geometric analysis, analyzing 
ECG recordings to create histograms of intervals sorted into 7.8 ms bins.  
There are several new non-linear indices being examined that go beyond time and 
frequency domains. These forms of HRV indices essentially allow one to attempt 
to quantify the unpredictability and natural randomness of a time series 
measurement. Dyx, a non-linear HRV measure utilizing density analysis, derives 
HRV information from both time and frequency domains, reflecting the increasing 
randomness in RR interval series (4). There are various other non-linear measures 
of HRV that are calculated by extracting correlations of different RR intervals over 
various time scales, such as detrended fluctuation analysis (DFA) alpha1 or 
alpha2, approximate and sample entropy (ApEn, SampEn), and D2 (3). Poincaré 
plots, a scatter plot of each RR interval against its previous interval, allow for 
discovery of patterns within various time series. Analysis of such plots yields the 
non-linear measurements of S, SD1, and SD2. These indices, derived from base 
concepts rooted in chaos theory and fractals, may demonstrate more accurate 
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insights into the autonomic health of the heart, supported by evidence that the 
cardiovascular system may function in a non-linear manner (4). 
 
As availability of hearts for transplant plateaus with everchanging UNOS allocation 
criteria, MCS, and, specifically LVADs, provide an effective strategy for patients 
with HF whether used as a bridge to transplant or as a destination therapy. A 
mechanically unloaded heart following LVAD implantation demonstrates reverse 
remodeling and a signature of myocardial recovery. Following implantation of the 
VAD, HeartWare’s HVAD® (Medtronic) records HRV regularly, suggesting that it is 
a valuable parameter for the assessment of cardiac recovery in patients. There 
have been various studies investigating the prognostic information HRV can 
provide about patients with CHF, as well as more broadly the relationship between 
HRV and the health of the body’s cardiac autonomic nervous system (ANS) (2). 
Therefore, HRV measurement could be utilized as a metric for stratifying end-
stage CHF patients, predicting acute decompensation or ventricular 
tachyarrhythmias (VTA) development vs. recovery, and determining patient 
response to various therapeutics (LVAD vs. temporary VAD, i.e. Impella 
[Abiomed]) (Figure. 1).  
 
 
 
 
 
Figure 1. Heart rate variability (HRV) as a dynamic biomarker for end-stage 
congestive heart failure (CHF) stratification, CHF prognosis, Left Ventricular Assist 
Device (LVAD) complication prediction, and left ventricular (LV) recovery. 
Additional abbreviations: sudden cardiac death (SCD); ventricular tacharrhythmia 
(VTA); gastrointestinal bleeding (GiB); right ventricular failure (RVF) 
 
 
 
Methods 
 
Search Strategy 
 
PubMed, Ovid, and Google Scholar databases were searched using the terms 
“heart rate variability,” “HRV,” “VAD,” and “heart failure.” Full text articles were then 
obtained. Each article’s bibliography was searched for further studies and 
references that were not initially generated electronically.  
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Selection Criteria and Review Process 
 
Only English language publications involving adults of at least 18 years examining 
HRV were included. Due to the low volume of published research available, 
publications were not filtered or excluded based on type of HRV index studied.  
Data Synthesis 
 
122 total articles were identified. Data are presented as the time, frequency, and 
non-linear domains of HRV as reported within the literature. 
 
Results 
 
HRV: CHF Stratification, Prognosis, and Recovery 
 
HRV is frequently deranged in CHF patients secondary to chronic, inappropriate 
sympathetic activation with withdrawal of parasympathetic tone. However, even 
amongst “healthy” patients without heart disease, each person’s baseline HRV 
values vary person to person (5). It is well established that HRV values are 
severely attenuated in CHF patients compared with normal controls (2). There 
have been a select number of studies aiming to establish means of differentiating 
and stratifying CHF patients from healthy patients without cardiac disease, citing 
significant differences in predominantly frequency-domain indices including 
HF/VLF, LF, VLF, LF/HF (6, 7).  
Depressed HRV is an independent predictor for all-cause mortality, cardiac 
decompensation, and sudden cardiac death (SCD) in end-stage HF patients (2). 
Significantly decreased SDNN has demonstrated utility in contributing to a 
dynamic risk score for evaluating 30-day HF hospitalization, as an independent 
predictor for cardiac death, all-cause death, transplant, or worsening CHF in 
reduced LVEF patients, and a prognostic marker for all-cause mortality or SCD in 
CHF patients (8-15). As SDNN reflects the overall autonomic health of the cardiac 
system, CHF patients with attenuated cardiac ANS are expected to present with 
lower SDNN values as compared to healthy controls (3). The varying levels of 
SDNN cutoffs reflect both the person-to-person differences in baseline HRV 
values, as well as the possibility for a gradient of worsening clinical presentation 
correlated to severity of affected SDNN. Diminished daytime LF(ln) values, night 
LF, night HF, and LF/HF ratios were independent predictors for all-cause mortality 
and cardiac events (12, 14-17). LF, representative of the baroreflex activity at rest, 
largely demonstrates similar prognostic power compared with time-domain indices 
such as SDNN and SDANN (3). Limited studies demonstrate low utility in HF, 
reflective of the PNS activity and HR variations as related to respiration, for 
prediction of all-cause mortality or SCD (10). However, the finding of nocturnal HF 
≤60 as predictive of SCD by Guzzetti et al. perhaps sheds insight into the influence 
of circadian cycle and changes in respiration on HRV (17). LF/HF is a calculated 
ratio derived to observe the balance between the SNS and PNS. Despite its 
controversial nature regarding what it actually measures, it has been repeatedly 
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demonstrated as an independent predictor for SCD and cardiac events (12, 18). 
Non-linear HRV measures of alpha1, IMAI2, and IVP, which may serve as more 
accurate representations of the cardiac ANS, have also been shown to have 
predictive value in CHF patients (19-20).  
There is limited data with regards to HRV as a predictor for LV recovery in CHF 
patients. A study by Landolina et al. found that in CHF patients undergoing CRT 
device implantation, SDANN was a significant predictor for all-cause mortality or 
urgent transplantation (21). While the number of studies is limited, this 
demonstrates the ability to utilize HRV as a predictor for not just clinical decline, 
but as a monitor for patient recovery in end-stage CHF as well.   
HRV for LVAD Complication Prediction 
 
There is no established published literature to date discussing HRV indices as 
prognostic markers for development of new-onset MCS device complications in 
VAD-dependent end-stage CHF patients. The most common complications 
secondary to MCS devices include device thrombosis, gastrointestinal bleeding 
(GiB), aberrant VTA, and RV failure (RVF) (1). While there is a lack of studies 
comparing HRV with onset of GiB or RVF, there are a handful of preliminary 
studies examining the prognostic value of frequency-domain (LF, VLF) and non-
linear (Dyx, DFA) HRV indices in predicting new onset malignant VTA in CHF 
patients (2, 22-24). While studies do not directly target device thrombosis events, 
there are publications that broadly encompass various biomarkers playing key 
roles in the pathogenesis of thrombus formation (inflammation, hemostasis, 
thrombosis), and these HRV markers could potentially be extrapolated as starting 
values to test HRV changes with new onset device thrombosis complications in 
LVAD patients. Cardiac ANS tone has been shown to be related to platelet-
induced thrombosis via alpha-2 receptor mediation (25). In a study by Hamaad et 
al., reduced mean RR interval (853) was weakly associated with increased P-
selectin and D-dimer, two markers of thrombosis, in patients admitted for acute 
coronary syndrome requiring PCI intervention and thrombolysis (25). In a similar, 
earlier study by the same group, there was a modest association between reduced 
RR interval and HRV indices (mean SDNN 42, mean SDNNi 34, mean triangular 
index 10.0, mean VLF 674) with increased inflammatory markers (white cell count, 
IL-6, CRP) in acute coronary syndromes patients (26). It is important to note that 
both of these studies had exclusion criteria of LVEF <40%, Killip class III/IV 
symptoms, atrial fibrillation or other arrhythmia, and severe valvular disease. While 
these studies examined HRV in acute MI patients without history of CHF, reduced 
HRV has been similarly shown to predict cardiovascular morbidity and mortality in 
this patient population (2).  
With no clinical studies having been performed to date that generate specific HRV 
cutoff target values that would precisely suggest negative outcomes to date, these 
are data that must be uniquely identified and rigorously tested in order to 
eventually be utilized to improve patient outcomes.  
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HRV for LV Recovery in LVAD Therapy 
HRV has been sparingly studied as a biomarker for CHF reverse remodeling 
secondary to LVAD therapy. As the left ventricle is unloaded, reverse remodeling 
may occur with restoration of the cardiac ANS and improved HRV indices. There 
are a few studies examining the LV off-loading effects of LVAD therapy in end-
stage CHF patients, as monitored by HRV indices. A study by Kim et al. evaluating 
LVAD therapy in 3 patients demonstrated improved HRV indices (RR 587 to 677, 
RRSD 8.1 to 27.2, LF increased by 5.2, HF increased by 2.1, LF/HF increased to 
2.3 from 1.07) at time of transplant compared with values the day before LVAD 
implantation, suggestive of improved ANS activity and SNS/PNS balance 
secondary to the device therapy (27). A study by Cooley et al demonstrated 
restoration of LF oscillations of RR-intervals in 2 patients as early as 1-month 
status-post LVAD therapy, previously absent on ECG pre-implant (28). A study by 
Gardiwal et al demonstrated significantly improved HRV measures in patients with 
LVAD therapy compared with CHF patients with medical optimization (29). SDNN 
improved to 108 from 67, SDANN improved to 103 from 56, and triangular index 
improved to 29 from 18. A study by Imamura et al. demonstrated that in 
continuous-flow LVAD’s, high rotational speeds were correlated with lower 
LF(normalized unit) ratios (LF/[LF+HF]), increased HF values, improved cardiac 
index, and lower PCWP (30). Studying LF(NU) as a way to measure the proportion 
of SNS to PNS activity, data stratification with a LF(NU) cutoff of 55% 
demonstrated statistically significant improved LVEF in stage D, CHF patients at 6-
months post-LVAD implantation, suggesting the importance of high-speed settings 
in MCS patients with baseline elevated HRV indices and high risk for induced 
ventricular tachyarrhythmias. A study by Nunan et al indicated lower LF(ln) and 
LF(NU), and LF/HF values for CHF patients when compared with healthy controls, 
explanted patients after LVAD therapy, and patients currently on LVAD therapy 
(2). LF is an independent predictors of mortality in CHF patients, with LF values 
ranging from <3.3 (LF(ln)) to <13-20 (LF(NU)) as statistically significant markers as 
compared to estimated normal values of 5.0 and 519, respectively. Furthermore, 
they demonstrated that the mean LF of explanted patients was similar to controls, 
which held LF values within the normal range. LF/HF, reflecting the balance of 
SNS and PNS, is another independent predictor of mortality, with various studies 
suggesting cutoffs of <0.37 and <0.43. These values among explanted, implanted, 
and control patients were also nearly identical. The significantly elevated LF and 
LF/HF values when compared to CHF patients suggests an improvement in 
cardiac ANS regulation secondary to device therapy that is noticeable during 
ongoing therapy and remains post-explantation.  
Thus, a handful of the cutoff values posited by the aforementioned studies utilizing 
HRV time indices (SDNN, SDANN, triangular index, RR, RRSD) and frequency 
indices (LF, HF, LF/HF) may serve as worthwhile starting points for future testing 
via various diagnostic modalities (4, 27, 29). 
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Discussion 
End-stage CHF is marked by unregulated activation of the cardiac SNS pathways, 
which further deteriorates myocardial cell recovery and ventricular modeling. As 
HF therapy progresses toward preferential destination therapy, there needs to be a 
more frugal understanding of the causes LVAD complications and LV recovery 
following therapy. With new UNOS allocations for orthotropic cardiac 
transplantation further limiting available organs based on patient complications 
(hemolysis, pump thrombosis, RVF, device infection, mucosal bleeding), more 
patients are entering the mechanotrope era with MCS devices becoming the 
standard of care both as bridge to transplant as well as destination therapy. 
Reliable durable LVAD devices (HVAD, HeartmateTM 3 [Abbott]) are currently 
available on the market that treat dysfunctional end-stage CHF by a mechanism of 
LV unloading, ameliorating end-organ hypoperfusion, and ultimately promoting 
improved cardiac ANS innervation. There are also VAD’s available for acute 
cardiogenic shock intervention and bridge to transplant (Impella® [Abiomed], 
TandemHeart® [LiveNova]). While there continue to be vast improvements with 
device design and surgical implantation technique, VAD therapy-derived 
complications continue to pose significant clinical risk to patients. As 
aforementioned, there are several studies demonstrating HRV as a static variable 
for risk stratification and clinical prognosis in CHF patients (2, 6, 7). However, 
there is a significant gap in the field examining utility of HRV in MCS device 
patients specifically. With variable individual patient response to VAD therapy, 
there is a need for diagnostics and clinical biomarkers to aid in physician decision 
making regarding choice of surgical intervention and choice of MCS device.  
Machine learning (ML) and neurolinguistic programming (NLP) are a new frontier 
of research, utilizing artificial intelligence (AI) to further predictive strategies and 
overall advancements in the field of medicine. Various models have been 
proposed utilizing AI for more accurate diagnosis methodology and patient 
complication prediction, such as computer-aided detection of diabetic retinopathy, 
prediction of cancer evolution, and identification of neck of femur fractures. A study 
by Zverinski et al. utilized recurrent neural networks to predict mortality, renal 
failure, and bleeding in the critical care unit after cardiothoracic surgery with PPV's 
>=0.84 (31). Another study by Iqbal et al. utilized deep deterministic learning that 
combined predefined ECG-recognizable patterns of ST-T changes and flattened T-
waves with fused datasets to derive a 99.97% accurate pattern recognition 
algorithm to diagnosis myocardial infarction (32). Choi et al. utilized recurrent 
neural network models with gated recurrent units for detection of new-onset HF, 
achieving a statistically higher AUC of 0.883 compared with baseline diagnostic 
methods (33). 
HRV and Machine Learning 
Studies have examined the potential for HRV in combination with machine 
learning. Lee et al. demonstrated one of the first uses of HRV, combined with 
respiratory rate variability (RRV), with an artificial neural network (ANN) utilizing 13 
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hidden neurons in 1 hidden layer, that was able to predict VTA one hour before 
occurrence with an accuracy of 85.3%, sensitivity of 73.3%, and specificity of 
73.8% (34). Of note, the significant HRV indices demonstrated were SDNN (time-
domain) and SD2 (non-linear) with predictive values of 0.073 and 0.098, 
respectively. As 1 layer represents a rather shallow network, it demonstrates the 
potential for better accuracy if a deeper network, perhaps with convolutional neural 
network layers, were constructed. A study by Nagaraj et al. integrated HRV with 
support vector machine (SVM) machine learning algorithm to create a four-state 
classifier to classify sedation level of ICU patients (35). Compared with RASS 
scores, the algorithm achieved 69% accuracy in discriminating between the 4 
sedation levels proposed, and 79% accuracy discriminating between sedated and 
non-sedated states. Another study paired SVM with various combinations of non-
standard HRV measures (SUM_TD, SUM_FD, SUM_IE) in an effort to properly 
detect new-onset CHF in patients (36). At peak performance, the algorithm was 
able to achieve 100% accuracy, sensitivity, and specificity. In addition, Liu et al. 
utilized machine learning to improve 1-year prediction of cardiovascular death 
post-acute coronary syndrome by Beatquency (novel measurement of variation of 
frequency of heartbeats), increasing the AUC from 0.730 to 0.753 (37).  
Future Directions 
Current MCS devices continually measure and record various biomarkers, with the 
ability to derive HRV from device pump waveform analysis without ECG or ICD 
requirement. Moscato et al. examined continuous pump-derived HRV monitoring in 
LVAD patients compared to HRV values calculated by traditional ECG 
measurement demonstrated statistically similar values within 10ms for the time-
domain indices of RR, SDNN, RMSSD, and pNN50 (38). With accurate 
measurements, this sets the stage for HRV as an easily attainable and cost-
effective biomarker in LVAD patients for monitoring both complications as well as 
recovery.  
While decreased HRV has been studied as a predictor for mortality and morbidity 
in general CHF patients, there is no studies discussing HRV indices as prognostic 
biomarkers for LVAD complications in MCS device patients. Furthermore, current 
literature extensively examines different HRV indices (i.e. SDNN, LF/HF) for static 
cutoffs predictive of clinical decline. However, with each patient’s unique 
individualized baseline HRV values, there is a need to study the changes in 
sequences of HRV data, rather than treating them as independent variables. By 
using machine-readable HRV data in conjunction with cutting-edge machine 
learning and neural network algorithms, end-stage CHF patients may be better 
stratified, with derivation of HRV cutoffs predicting acute decompensation, 
improvement from LVAD implantation, LVAD complications, and ultimately LV 
reverse remodeling. Sequence modeling utilizing hidden Markov models, recurrent 
neural networks, or long-term short-term memory (LSTM) may better stratify CHF 
with better accuracy. By training each neural network independently for a different 
complication or clinical status, new HRV trends may be uncovered which predict 
the next most probably sequence for prediction of complication or recovery. With 
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the emergence of wearable devices and smart watches measuring heart rate and 
other diagnostic parameters, HRV continues to be a challenging but solvable index 
to measure. Individual devices set the stage for a new form of personalized 
precision healthcare, and predictive algorithms utilizing HRV and other biomarkers 
loaded on to such devices may provide real-time and dynamic insight into 
individualized patients’ clinical statuses.  
Limitations 
A major limitation consistent across all studies is the retrospective nature of 
analysis examining small patient populations at single centers. Furthermore, many 
studies utilized age and gender-matched controls to compare HRV data to device 
patients that were studied. However, pre-MCS implantation HRV data was not 
available for these device patients, making it difficult to compare how HRV values 
may have changed from pre-device baseline values. Moving forward, longitudinal 
studies tracking HRV changes pre- and post- LVAD implantation in end-stage CHF 
patients are necessary to accurately establish predictive cutoffs for 
decompensation, complications, and recovery.  
While deep learning methods can surpass classical rule-based methods on large 
data sets, their success is hampered by the use of hard to interpret hidden layers. 
These layers are currently treated as black boxes, making it hard to derive 
meaningful inferences from them and reason as to why the model works or it does 
not. This lack of transparency can make it hard to rationalize the success of a 
model in medical field, where the stakes of mis-classification are much higher 
compared to other applications of AI. This problem is exasperated with the rising 
popularity of ResNet based (Residual network) architectures which can have as 
many as 200 hidden layers. While this is still an active area of research recent 
work such as Grad-Cam (Gradient-weighted class activation mapping) aims at 
visualizing parts of what the hidden layers are doing by employing heat maps and 
pixel-space gradient techniques to visualize various features in deep neural 
networks (39). Unlike its predecessor model, CAM (Class activation mapping) it 
does not need the network to confirm to a certain architecture and is able to 
produce results even in the presence of dense layers which are unable to retain 
spacial information (40). Grad-Cam has been shown to perform well for CNN with 
fully connected layers such as VGG, CNN used for structured output such as 
captioning of describing images (CNN + LSTM) and for multi-modal inputs (41-42). 
It is interesting to note that not only can we use these methods to rationalize the 
workings of deep networks but we can also use them to give us insight into new 
predictive associations which might not have been previously possible for doctors 
to make. 
Conclusion 
HRV is a dynamic, inexpensive, and readily measurable biomarker with promising 
utility in monitoring of end-stage CHF patients on LVAD therapy, as a means of 
risk stratification, complication prediction, and recovery prediction. 
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